

Primary Immune Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P03245012600EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: P03245012600EN

Abstracts

The 7 major primary immune deficiency markets reached a value of US\$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 9.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The primary immune deficiency market has been comprehensively analyzed in IMARC's new report titled "Primary Immune Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary immune deficiency refers to a group of rare genetic disorders that impair the normal functioning of the immune system. These conditions are characterized by a weakened or absent immune response, making individuals more susceptible to infections, autoimmune diseases, and other health complications like cancer. The ailment can manifest in various ways, depending on the specific defect in the body's defense mechanism. The most common symptoms of the illness are recurrent, severe, or unusual infections that can affect different body systems, including the respiratory tract, skin, and gastrointestinal tract. Children suffering from this ailment may also experience growth problems, failure to thrive, developmental delays, etc. Primary immune deficiency is typically diagnosed through a combination of clinical feature evaluation, medical history review, and a physical examination. The healthcare provider may further conduct genetic testing to identify specific gene mutations causing the underlying indications in patients. Numerous laboratory tests and blood workups, such as functional assays, lymphocyte subsets, complete blood counts, etc., are also performed to assess and indicate any abnormalities within the immune system.

The increasing cases of genetic variations that can either be inherited from one or both parents or occur spontaneously are primarily driving the primary immune deficiency

market. In addition to this, the rising incidences of phagocytic cell disorders, in which the immune system's ability to ingest and kill microorganisms through neutrophils and monocytes is impaired, are further bolstering the market growth. Moreover, the widespread adoption of hematopoietic stem cell transplantation, since it helps to improve immune function and provide protection against infections, is also creating a positive outlook for the market. Apart from this, the inflating application of granulocyte colony-stimulating factor (G-CSF) therapy that encourages the bone marrow to produce and release white blood cells, thereby significantly enhancing the quality of life for patients, is further augmenting the market growth. Additionally, the escalating popularity of gene therapy, which is intended to address the underlying genetic cause of the ailment and potentially reduce the need for frequent treatments, is expected to drive the primary immune deficiency market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the primary immune deficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary immune deficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary immune deficiency market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary immune deficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary immune deficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary immune deficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the primary immune deficiency market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the primary immune deficiency market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the primary immune deficiency market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of primary immune deficiency across the seven major markets?

What is the number of prevalent cases (2018-2034) of primary immune deficiency by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of primary immune deficiency by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with primary immune deficiency across the seven major markets?

What is the size of the primary immune deficiency patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of primary immune deficiency?

What will be the growth rate of patients across the seven major markets?

Primary Immune Deficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for primary immune deficiency drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary immune deficiency market?

What are the key regulatory events related to the primary immune deficiency market?

What is the structure of clinical trial landscape by status related to the primary immune deficiency market?

What is the structure of clinical trial landscape by phase related to the primary immune deficiency market?

What is the structure of clinical trial landscape by route of administration related to the primary immune deficiency market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PRIMARY IMMUNE DEFICIENCY - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PRIMARY IMMUNE DEFICIENCY - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PRIMARY IMMUNE DEFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)
 - 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PRIMARY IMMUNE DEFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PRIMARY IMMUNE DEFICIENCY - UNMET NEEDS

10 PRIMARY IMMUNE DEFICIENCY - KEY ENDPOINTS OF TREATMENT

11 PRIMARY IMMUNE DEFICIENCY - MARKETED PRODUCTS

- 11.1 List of Primary Immune Deficiency Marketed Drugs Across the Top 7 Markets
 - 11.1.1 HyQvia (Immune globulin) - Takeda
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Flebogamma (Immune globulin) - Grifols
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Privigen (Immune globulin) - CSL Behring
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Asceniv (Immune globulin) - ADMA Biologics
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Panzyga (Immune globulin 10%) - Octapharma
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PRIMARY IMMUNE DEFICIENCY - PIPELINE DRUGS

- 12.1 List of Primary Immune Deficiency Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 GC 5107 - GC Biopharma
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Treosulfan - Medac
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 BPX501 - Bellicum Pharmaceuticals
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PRIMARY IMMUNE DEFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PRIMARY IMMUNE DEFICIENCY – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 PRIMARY IMMUNE DEFICIENCY - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Primary Immune Deficiency - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Primary Immune Deficiency - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Primary Immune Deficiency - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany

- 15.4.1 Primary Immune Deficiency - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
- 15.4.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Primary Immune Deficiency - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Primary Immune Deficiency - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Primary Immune Deficiency - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Primary Immune Deficiency - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Primary Immune Deficiency - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Primary Immune Deficiency - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Primary Immune Deficiency - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Primary Immune Deficiency - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Primary Immune Deficiency - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Primary Immune Deficiency - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Primary Immune Deficiency - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Primary Immune Deficiency - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Primary Immune Deficiency - Access and Reimbursement Overview

16 PRIMARY IMMUNE DEFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PRIMARY IMMUNE DEFICIENCY MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 PRIMARY IMMUNE DEFICIENCY MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Primary Immune Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P03245012600EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P03245012600EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

